Biocept, Inc. (BIOC)
| Market Cap | 54.82M |
| Revenue (ttm) | 43.77M |
| Net Income (ttm) | -6.87M |
| Shares Out | 13.40M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $3.91 |
| Previous Close | $4.18 |
| Change ($) | -0.27 |
| Change (%) | -6.46% |
| Day's Open | 3.90 |
| Day's Range | 3.88 - 4.09 |
| Day's Volume | 294,929 |
| 52-Week Range | 3.46 - 13.00 |
Biocept Inc (NASDAQ: BIOC) received a favorable final Local Coverage Determination expanding Medicare coverage for the use of its Target Selector assay to identify the HER2 biomarker from circulating tu...
SAN DIEGO--(BUSINESS WIRE)-- #breastcancer--Biocept receives Medicare coverage for breast cancer assay to detect and analyze HER2 biomarker and announces CNSide and COVID-19 testing updates.
SAN DIEGO--(BUSINESS WIRE)--Biocept appointed Linda Rubinstein and Antonino Morales to its Board of Directors, and named Director Samuel D. Riccitelli as Chairman of the Board.
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at th...
SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept was awarded a South Korean Patent for its Primer-Switch technology, which identifies rare genetic mutations, including cancer biomarkers.
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Russell_Microcap_Index--Biocept joins the Russell Microcap Index
SAN DIEGO--(BUSINESS WIRE)--Biocept and Quest Diagnostics collaborate to provide NGS-based liquid biopsy testing to aid therapy selection and monitoring for lung cancer patients.
SAN DIEGO--(BUSINESS WIRE)--Biocept received more than 420,000 samples for COVID-19 testing since launching service in June 2020.
SAN DIEGO--(BUSINESS WIRE)--Biocept and CLEARED4 to develop new system for tracking and managing COVID-19 testing for campuses and other facilities returning to full capacity.
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present at the LD...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...
Biocept Inc (NASDAQ:BIOC) (FRA:B003) started 2021 on a high with a profitable first quarter on revenue of $17.8 million, driven primarily by its coronavirus (COVID-19) tests. For the period ended March...
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept reports profitability for the second consecutive quarter on revenues of $17.8 million for the first quarter of 2021.
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ...
Biocept Inc (NASDAQ:BIOC) has said it is partnering with the Foundation for California Community Colleges to make coronavirus (COVID-19) testing available for the state‘s 116 community colleges and thei...
SAN DIEGO--(BUSINESS WIRE)--Biocept to provide COVID-19 testing to California community colleges and their more than 2.1 million students through FCCC partnership.
Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer
Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced the full commercial launch of CNSide, the company's cerebrospinal fluid (CSF) assay designed to better detect and manage the treatment of metastatic cancer...
SAN DIEGO--(BUSINESS WIRE)-- #cancer--Biocept announces full launch of CNSide, its CSF assay designed to improve the management of metastatic cancers involving the central nervous system.
Biocept Inc (NASDAQ:BIOC) (FRA:B003) reports that since the company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples. These test samples are proce...
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #Biocept--Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) will host a webinar featuring leading neuro-oncologists to discuss the use of the Company's proprietary cerebrospinal fluid (CSF) assay for diagn...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...
Biocept Inc (NASDAQ:BIOC) (FRA:B003) will host a webinar featuring leading neuro-oncologists to discuss the use of its proprietary cerebrospinal fluid (CSF) assay for diagnosing and managing tumors that...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will host a webinar featuring leading neuro-oncologists to discuss the...
Biocept Inc (NASDAQ:BIOC) swung to a profit in its fourth-quarter thanks to its coronavirus (COVID-19) testing driving revenue to $18.5 million. For the period ended December 31, 2020, the San Diego-bas...
Shares of Biocept (NASDAQ:BIOC) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 170.00% over the past year to $0.14, which beat the ...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 3...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and 12 ...
Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to date m...
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Deciph...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that President and CEO Michael Nall will participate in thre...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purcha...
Biocept Inc (NASDAQ:BIOC) and privately held life sciences company Aegea Biotechnologies Inc have announced a supply agreement for a new PCR-based coronavirus (COVID-19) assay kit designed by Aegea and ...
SAN DIEGO--(BUSINESS WIRE)--Aegea Biotechnologies & Biocept enter supply agreement to validate and commercialize new COVID-19 test to help screen, manage, and evaluate patients.
Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC)...
Biocept Inc (NASDAQ:BIOC) announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of EGFR mutat...
SAN DIEGO--(BUSINESS WIRE)--Biocept and Protean BioDiagnostics Collaborate to Demonstrate Advantages of Biocept's Target Selector Assay for Non-Small Cell Lung Cancer Patients.
Biocept Inc (NASDAQ:BIOC) announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50% of tissue biopsy specimens from non-small cell lung cancer patients that were dee...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay ki...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, provides an update on its...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable in...
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, ann...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically a...
SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...
SAN DIEGO, Dec. 30, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...
Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2020 Results - Earnings Call Transcript
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically ...
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically a...
About BIOC
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lun... [Read more...]
| Industry Diagnostics & Research | IPO Date Feb 5, 2014 |
| CEO Michael Nall | Employees 104 |
| Stock Exchange NASDAQ | Ticker Symbol BIOC |
Financial Performance
In 2020, Biocept's revenue was $27.46 million, an increase of 396.72% compared to the previous year's $5.53 million. Losses were -$17.81 million, -29.16% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for Biocept stock is "Buy" and the 12-month stock price forecast is 12.00.